Because weakness is a common symptom of many other disorders, the diagnosis of myasthenia gravis is often missed or delayed sometimes up to two years in people who experience mild weakness or in those individuals whose weakness is restricted to only a few muscles.
Today, myasthenia gravis can generally be controlled. There are several therapies available to help reduce and improve muscle weakness. With treatment, most individuals with myasthenia can significantly improve their muscle weakness and lead normal or nearly normal lives. Some cases of myasthenia gravis may go into remission—either temporarily or permanently— and muscle weakness may disappear completely so that medications can be discontinued. Stable, long-lasting complete remissions are the goal of thymectomy and may occur in about 50 percent of individuals who undergo this procedure.
The mission of the National Institute of Neurological Disorders and Stroke NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.
Although there is no cure for myasthenia gravis, management of the disorder has improved over the past 30 years. There is a greater understanding about the causes, structure and function of the neuromuscular junction, the fundamental aspects of the thymus gland and of autoimmunity.
Technological advances have led to more timely and accurate diagnosis of myasthenia gravis and new and enhanced therapies have improved treatment options. Researchers are working to develop better medications, identify new ways to diagnose and treat individuals, and improve treatment options. Some people with myasthenia gravis do not respond favorably to available treatment options, which usually include long-term suppression of the immune system.
New drugs are being tested, either alone or in combination with existing drug therapies, to see if they are more effective in targeting the causes of the disease. In addition to developing new medications, researchers are trying to find better ways to diagnose and treat this disorder.
For example, NINDS-funded researchers are exploring the assembly and function of connections between nerves and muscle fibers to understand the fundamental processes in neuromuscular development. This research could reveal new therapies for neuromuscular diseases like myasthenia gravis. New treatment options Findings from a recent NINDS-supported study yielded conclusive evidence about the benefits of surgery for individuals without thymoma, a subject that had been debated for decades.
Researchers hope that this trial will become a model for rigorously testing other treatment options, and that other studies will continue to examine different therapies to see if they are superior to standard care options. Assistive technologies, such as magnetic devices, may also help people with myasthenia gravis to control some symptoms of the disorder. Box Bethesda, MD www. Myasthenia Gravis Foundation of America, Inc. Muscular Dystrophy Association N.
Clark, Suite Chicago, IL www. NIH Publication No. It is not intended to be medical opinion, nor is it a substitute for personal professional medical care.
Increase Text Size. These steps may be taken to confirm a diagnosis of MG: Neurological exam: This may include testing your reflexes, muscle strength, muscle tone, senses of touch and sight, gait, posture, coordination, balance and mental skills. Impaired eye movement or muscle weakness may prompt a doctor to evaluate further. Blood tests to measure myasthenic antibodies in the blood: About 80 to 85 percent of MG patients test positive for AChR antibodies — antibodies to the acetylcholine receptor — in their blood.
A positive antibody supports the diagnosis of MG, but a higher number or titer of this antibody does not correlate with more severe disease. Another 5 to 10 percent are found to have antibodies to muscle-specific serum kinase MuSK , a protein that helps organize ACh receptors on the muscle cell surface.
This antibody also can be tested for in the blood. A blood test for the LRP4 antibody is not yet commercially available. Share on: Facebook Twitter. Show references AskMayoExpert. Myasthenia gravis. Rochester, Minn. Clinical overview of MG. Myasthenia Gravis Foundation of America. Accessed April 1, Jameson JL, et al. Myasthenia gravis and other diseases of the neuromuscular junction. In: Harrison's Principles of Internal Medicine.
New York, N. Myasthenia gravis fact sheet. National Institute of Neurological Disorders and Stroke. Simon RP, et al. Motor disorders. In: Clinical Neurology. Jordan A, et al. Recent advances in understanding and managing myasthenia gravis.
Bird SJ. Overview of the treatment of myasthenia gravis. Thymectomy for myasthenia gravis. Accessed April 4, Myasthenia gravis: A guide for patients. Brown AY. Allscripts EPSi. Mayo Clinic. April 13, Related Receptors for neurotransmitters Thymus gland. Mayo Clinic in Rochester, Minn. Learn more about this top honor.
0コメント